Tetraphase Pharmaceuticals Inc (TTPH) Expected to Post Quarterly Sales of $2.09 Million
Wall Street brokerages forecast that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will post $2.09 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Tetraphase Pharmaceuticals’ earnings. The lowest sales estimate is $1.50 million and the highest is $3.31 million. Tetraphase Pharmaceuticals posted sales of $4.07 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 48.6%. The firm is scheduled to report its next quarterly earnings results on Thursday, November 1st.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $16.68 million for the current year, with estimates ranging from $8.00 million to $21.28 million. For the next financial year, analysts forecast that the firm will post sales of $22.61 million per share, with estimates ranging from $12.00 million to $46.03 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.18. The business had revenue of $11.58 million during the quarter, compared to analyst estimates of $2.23 million. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%.
Shares of TTPH stock traded down $0.07 during trading hours on Friday, reaching $3.07. The company had a trading volume of 439,103 shares, compared to its average volume of 1,261,593. Tetraphase Pharmaceuticals has a 12-month low of $2.05 and a 12-month high of $7.98.
Institutional investors have recently modified their holdings of the stock. Flagship Harbor Advisors LLC purchased a new position in Tetraphase Pharmaceuticals in the second quarter worth approximately $104,000. Cubist Systematic Strategies LLC grew its position in Tetraphase Pharmaceuticals by 232.1% in the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 24,837 shares during the period. Canada Pension Plan Investment Board purchased a new position in Tetraphase Pharmaceuticals in the second quarter worth approximately $179,000. Dynamic Technology Lab Private Ltd grew its position in Tetraphase Pharmaceuticals by 322.1% in the first quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 58,079 shares during the period. Finally, Alambic Investment Management L.P. purchased a new position in Tetraphase Pharmaceuticals in the first quarter worth approximately $356,000. Institutional investors own 40.94% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Recommended Story: NASDAQ Stock Market Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.